Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 388

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 388
---
On January 1, 2023 € 456,352 1,529,405 3,474 1,989,230
Of which current portion: 133,470 230,022 2,139 365,631
Reclassification to liabilities directly associated with assets in disposal group classified as held for sale ( 60) ( 60)
Significant financing component (2) ( 645) ( 645)
Revenue recognition of upfront ( 361,412) ( 230,242) ( 591,654)
Revenue recognition of milestones ( 68,027) ( 68,027)
Other movements ( 1,382) ( 1,382)
On December 31, 2023 € 26,268 1,299,163 2,032 1,327,463
Of which current portion: 25,054 230,070 1,146 256,270
Significant financing component (2) ( 227) ( 227)
Revenue recognition of upfront ( 21,952) ( 230,182) ( 252,134)
Revenue recognition of milestones ( 4,089) ( 4,089)
Other movements 339 339
On December 31, 2024 € - 1,068,981 2,371 1,071,352
Of which current portion: - 230,105 2,371 232,476
(1) The upfront received and the outstanding balance comprise the issuance liabilities for the warrants and the upfront payment allocated to the drug discovery platform.
(2) With regard to the additional consideration received for the extended cost sharing for filgotinib, we assume the existence of a significant financing component reflecting the time value of mone...
We refer to note 2 for a detail of the allocation of the transaction price of our collaboration with Gilead and to note 5 and note 7 for a description of our revenue recognition. 28. Business combinations during the prior periods
On June 21, 2022 we acquired, in an all-cash transaction,100% of the shares and voting interests of CellPoint for a total agreed payment at completion of €125million, including consideration for other liabilities associated with the transaction amounting to €10.3million. Additional contingent consideration up to €100.0million is due when certain milestones would be achieved.
On the same date we acquired all of the outstanding capital of AboundBio, for